This offers a novel mechanism whereby SMYD3 promotes the metastatic potential of ovarian cancer cells through ubiquitination and destabilization of p53, a critical regulator of carcinogenesis, independent of its methyltransferase activity. Here, SMYD3 is linked to ovarian carcinoma.